Study guide
2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization
Key Takeaways Explain This Topic AI
Atherosclerosis initiates with endothelial injury and subendothelial ApoB lipoprotein retention, where oxidized LDL is ingested by uninhibited macrophage scavenger receptors (SR-A, CD36) to form pathognomonic foam cells and fatty streaks.
Plaque vulnerability to acute rupture is governed by a thin fibrous cap (<65 µm), a large necrotic lipid core (>40% of plaque volume), and dense macrophage infiltration secreting collagen-degrading matrix metalloproteinases.
The critical diagnostic differentiator between unstable angina and NSTEMI is cardiac biomarker elevation: both present with ischemic chest pain and non-ST-elevation ECG changes, but only NSTEMI causes necrosis-induced elevations of high-sensitivity cardiac troponin.
Drug-eluting stents (DES) eluting antiproliferative agents (everolimus, zotarolimus) reduce in-stent restenosis to <5%, but mandate uninterrupted dual antiplatelet therapy (DAPT: aspirin plus a P2Y12 inhibitor) for a minimum of 6 to 12 months in ACS.
Left internal mammary artery (LIMA) bypass grafts achieve >90% patency at 10 years compared to ~50% for saphenous vein grafts, while sternotomy patients require strict sternal precautions for 6 to 8 weeks post-CABG.
Last updated: September 2026
2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization
Atherosclerotic coronary artery disease (CAD) remains the primary etiology for referral to secondary prevention cardiac rehabilitation. Clinicians must understand the cellular biology of plaque formation, the life-threatening mechanisms of plaque rupture, biomarker kinetics, and the clinical precautions accompanying contemporary percutaneous and surgical revascularization.
Cellular & Molecular Cascade of Atherogenesis
Atherosclerosis is a chronic, non-resolving inflammatory disease of the arterial wall initiated by endothelial injury and lipoprotein entrapment within the tunica intima : Endothelial Injury (Shear Stress, Smoking, HTN, Hyperlipidemia)
- -> Upregulation of Adhesion Molecules (VCAM-1, ICAM-1) & Loss of NO
- -> Subendothelial Retention & Oxidation of ApoB LDL Particles (ox-LDL)
- -> Monocyte Transmigration & Macrophage Differentiation
- -> Unregulated Scavenger Receptor Uptake (SR-A/CD36) --> FOAM CELLS
- -> Fatty Streak Formation
- -> Vascular SMC Migration & Fibrous Cap Synthesis
- -> Necrotic Core Expansion & Matrix Degradation (MMPs)
- -> Plaque Rupture / Erosion --> Occlusive Thrombosis
Endothelial Dysfunction: Chronic vascular insults—including disturbed oscillatory shear stress at arterial bifurcations, tobacco-derived free radicals, systemic hypertension, advanced glycation end-products (AGEs) in diabetes, and elevated circulating apolipoprotein B (ApoB) particles—impair endothelial integrity. Nitric oxide (NO) bioavailability drops sharply, causing local vasoconstriction, enhanced vascular permeability, and upregulation of leukocyte adhesion molecules ( VCAM-1, ICAM-1, and E-selectin ).
Lipoprotein Retention & Oxidation: Circulating low-density lipoproteins (LDL) enter the subendothelial space, binding to intimal extracellular proteoglycans. Trapped in this pro-oxidant microenvironment, LDL undergoes enzymatic and non-enzymatic modification into oxidized LDL (ox-LDL) . Ox-LDL is intensely cytotoxic and proinflammatory, stimulating endothelial cells and resident macrophages to secrete chemokines (such as MCP-1).
Monocyte Infiltration & Foam Cell Transformation: Circulating monocytes adhere to intimal VCAM-1 and transmigrate across the endothelium. Stimulated by macrophage colony-stimulating factor (M-CSF), monocytes differentiate into active tissue macrophages. These macrophages express scavenger receptors (SR-A and CD36) . Crucially, unlike physiological LDL receptors, scavenger receptors are not down-regulated by high intracellular cholesterol content. Macrophages engulf vast quantities of ox-LDL, becoming engorged with cytoplasmic lipid droplets and transforming into pathognomonic foam cells .
Fatty Streak Formation: Microscopic aggregates of foam cells coalesce within the subendothelial space to create the fatty streak —the earliest grossly visible lesion of atherosclerosis. Fatty streaks are present in many individuals by late adolescence and are initially reversible.
Fibrous Cap & Atheroma Maturation: Activated macrophages, T-lymphocytes, and platelets release platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF- β \beta β ). These cytokines stimulate vascular smooth muscle cells (VSMCs) in the tunica media to migrate into the intima, undergo phenotypic switching from a contractile to a synthetic phenotype, and deposit a dense extracellular matrix rich in type I and type III collagen . This collagenous structure forms the fibrous cap , which covers a central core of extracellular lipid, necrotic cellular debris, and cholesterol crystals.
Plaque Evolution: Fibrous Cap Dynamics & Plaque Vulnerability
Clinical presentation depends fundamentally on plaque architecture rather than luminal stenosis severity alone:
Stable Fibrous Plaque: Characterized by a thick, densely collagenous fibrous cap , a relatively small necrotic lipid core ( < 30 % <30\% < 30% of plaque volume), preserved VSMC content, and minimal local inflammation. These lesions cause progressive, fixed luminal narrowing, producing reproducible exertional chest tightness ( stable angina ) when myocardial oxygen demand exceeds supply.
Vulnerable (Unstable) Plaque: Pathologically defined as a Thin-Cap Fibroatheroma (TCFA) . Key morphological hallmarks include:
Thin fibrous cap: Measuring < 65 μ m <65\ \mu m < 65 μ m in thickness.
Large necrotic lipid core: Occupying > 40 % >40\% > 40% of total plaque volume.
Intense macrophage infiltration: Concentrated at the shoulder regions of the plaque.
Matrix Metalloproteinases (MMPs): Activated macrophages secrete MMP-1, MMP-8, and MMP-13 (collagenases), which degrade structural interstitial collagen while inhibiting VSMC matrix synthesis.
Intraplaque Neovascularization: Immature microvessels arising from the adventitial vasa vasorum are fragile and leaky, causing recurrent intraplaque hemorrhages that rapidly expand core volume.
Plaque Rupture vs. Superficial Erosion
When mechanical sheer forces overcome the degraded fibrous cap, the plaque ruptures (responsible for 65–75% of fatal acute infarctions) or undergoes superficial endothelial erosion (25–35%). Exposure of the thrombogenic necrotic core—specifically tissue factor and subendothelial collagen—to flowing blood triggers immediate platelet adhesion (via von Willebrand factor and GP Ib/IX receptors), activation (thromboxane A 2 A_2 A 2 and ADP release), aggregation (GP IIb/IIIa cross-linking with fibrinogen), and coagulation cascade activation, forming an intraluminal thrombus.
The Clinical Continuum of Acute Coronary Syndromes (ACS)
Acute coronary syndromes encompass a clinical spectrum driven by the extent and duration of coronary thrombotic occlusion:
Unstable Angina (UA): Characterized by transient, non-occlusive or subtotal thrombus formation. Patients present with ischemic discomfort occurring at rest (typically > 20 minutes >20\text{ minutes} > 20 minutes ), new-onset severe angina (CCS class III or IV within 2 months), or crescendo angina (distinctly more frequent, longer in duration, or lower in threshold). Resting ECG may demonstrate transient ST-segment depressions ( > 0.5 mm >0.5\text{ mm} > 0.5 mm ) or symmetric T-wave inversions. Critically, cardiac biomarkers (troponins) remain negative , indicating absence of irreversible myocardial cell necrosis.
Non-ST-Segment Elevation Myocardial Infarction (NSTEMI): Results from a mural, non-occlusive thrombus or transient complete occlusion with distal microembolization, causing patchy subendocardial myocardial necrosis. Symptoms mirror unstable angina, and ECG reveals ST depressions or T-wave inversions (or no acute changes). The defining clinical distinction is positive cardiac biomarkers (elevated high-sensitivity cardiac troponins).
ST-Segment Elevation Myocardial Infarction (STEMI): Results from acute, persistent, complete transmural occlusive coronary thrombosis . ECG reveals persistent J-point ST-segment elevation ≥ 1 mm \ge 1\text{ mm} ≥ 1 mm in two or more contiguous anatomical leads (or ≥ 1.5 – 2.5 mm \ge 1.5\text{--}2.5\text{ mm} ≥ 1.5 – 2.5 mm in precordial leads V2–V3, stratified by sex and age) or a new/presumed new left bundle branch block (LBBB). Requires immediate emergency reperfusion therapy.
High-Sensitivity Cardiac Troponin & Biomarker Kinetics
Biomarker Initial Rise Peak Concentration Duration of Elevation Clinical Role & Diagnostic Nuance
High-Sensitivity Cardiac Troponin I (hs-cTnI) 1–3 hours 12–24 hours 7–10 days Regulatory contractile protein; gold standard for myocardial necrosis; 99th percentile upper reference limit cutoff.
High-Sensitivity Cardiac Troponin T (hs-cTnT) 1–3 hours 12–24 hours 10–14 days Highly cardiospecific; binds tropomyosin; remains elevated longer; minor cross-reactivity in skeletal myopathies or ESRD.
Creatine Kinase-MB (CK-MB) 4–6 hours 18–24 hours 48–72 hours Rapid clearance makes it clinically useful to diagnose early re-infarction or recurrent ischemic necrosis within 14 days.
Reperfusion Time Windows: For STEMI, primary PCI must achieve a Door-to-Balloon (D2B) time < 90 minutes <90\text{ minutes} < 90 minutes at PCI-capable centers, or transfer for primary PCI with first medical contact-to-device time < 120 minutes <120\text{ minutes} < 120 minutes . If transfer cannot meet this window, systemic intravenous fibrinolysis must be initiated with a Door-to-Needle time < 30 minutes <30\text{ minutes} < 30 minutes .
Coronary Revascularization: PCI, Stent Technology & Pharmacotherapy
Percutaneous coronary intervention (PCI) restores luminal patency using advanced endovascular techniques:
Plain Old Balloon Angioplasty (POBA): Involves inflating a non-compliant balloon to fracture the plaque and stretch the media. Historically plagued by high acute elastic recoil and 6-month restenosis rates of 30% to 40% .
Bare-Metal Stents (BMS): Balloon-expandable metallic mesh scaffolds eliminated acute vascular recoil, but induced exaggerated vascular smooth muscle proliferation (neointimal hyperplasia), resulting in in-stent restenosis rates of 15% to 20% within 6 months.
Drug-Eluting Stents (DES): Contemporary standard of care. Consists of a thin cobalt-chromium or platinum-chromium metallic strut coated with a biocompatible durable or bioabsorbable polymer that elutes antiproliferative, cytostatic medications—principally everolimus, zotarolimus, or sirolimus . These agents arrest the VSMC cell cycle in the G 1 G_1 G 1 phase, reducing in-stent restenosis to < 5 % <5\% < 5% .
Dual Antiplatelet Therapy (DAPT) Mandatory Durations
Because DES antiproliferative coatings delay normal re-endothelialization of the metallic stent struts, flowing blood is exposed to prothrombotic metal surfaces:
Pharmacological Components: Aspirin (81 mg daily indefinitely; irreversible platelet COX-1 inhibitor) combined with a potent P 2 Y 12 P2Y_{12} P 2 Y 12 platelet receptor inhibitor :
Ticagrelor (90 mg BID): Direct-acting, reversible inhibitor.
Prasugrel (10 mg daily): Irreversible thienopyridine prodrug (contraindicated in patients with prior TIA or stroke).
Clopidogrel (75 mg daily): Irreversible prodrug requiring two-step hepatic CYP2C19 activation.
DAPT Duration: In patients presenting with Acute Coronary Syndromes , DAPT must be continued uninterrupted for a minimum of 6 to 12 months post-DES implantation.
Critical Safety Warning: Premature discontinuation of DAPT is the single strongest clinical predictor of acute or subacute stent thrombosis , an event that produces massive transmural STEMI with a case-fatality rate of 20% to 45% . In cardiac rehabilitation, any reported self-discontinuation of antiplatelet therapy requires immediate intervention and physician notification.
Surgical Revascularization: CABG Techniques & Conduit Patency
Coronary Artery Bypass Graft (CABG) surgery is indicated for high-complexity coronary disease: left main stenosis > 50 % >50\% > 50% , three-vessel disease with high SYNTAX scores ( > 22 >22 > 22 ), or two-vessel disease involving the proximal LAD in patients with diabetes mellitus or reduced LVEF ( < 50 % <50\% < 50% ).
Graft Conduit Selection & Long-Term Patency
Left Internal Mammary Artery (LIMA) to LAD: The absolute gold standard conduit. The LIMA (also called the left internal thoracic artery) is left attached to the subclavian artery and anastomosed distally to the LAD. Because its native arterial endothelium produces abundant continuous nitric oxide and prostacyclin and possesses a dense internal elastic lamina resistant to cellular penetration, LIMA-to-LAD grafts exhibit > 90 % to 95 % >90\%\text{ to }95\% > 90% to 95% patency at 10 years .
Saphenous Vein Grafts (SVG): Harvested from the medial lower extremity and reversed to prevent venous valve obstruction before anastomosis between the ascending aorta and target vessel. Venous conduits exposed to high systemic arterial pressures suffer endothelial denudation, macrophage infiltration, and accelerated vein graft atherosclerosis, resulting in only ~50% patency at 10 years .
Radial Artery Grafts: Harvested from the non-dominant forearm (following documentation of intact ulnar collateral circulation via a normal Allen test). Achieves ~80% to 85% 10-year patency , but requires calcium channel blocker therapy to prevent graft vasospasm.
Cardiopulmonary Bypass (CPB) & Postoperative Complications
Conventional "on-pump" CABG utilizes cardiopulmonary bypass, which induces a systemic inflammatory response, transient cognitive blunting ("pump head"), fluid retention, and hemodilution. Postoperative atrial fibrillation (POAF) develops in 25% to 40% of patients, peaking between postoperative days 2 and 4. Telemetry surveillance in early Phase II CR is vital for detecting asymptomatic POAF.
Sternal Precautions & Post-Surgical Phase II Rehabilitation
Following a median sternotomy, bony osteosynthesis of the divided sternum requires 6 to 8 weeks to reach stable tensile union.
Traditional Sternal Precautions (Prescribed for 6 to 8 Weeks)
Weight Lifting Restriction: Do not lift, push, or pull anything weighing more than 5 to 10 pounds (equivalent to a gallon of milk).
Bilateral Movement Restriction: Avoid unilateral rearward reaching, deep thoracic hyperextension, or violent horizontal shoulder abduction.
Sternal Splinting: Hug a firm cardiac pillow across the chest during all episodes of coughing, deep breathing, or sneezing to absorb peak intrathoracic distraction forces.
Mobility Restrictions: Avoid driving for 4 to 6 weeks (due to airbag deployment force and steering torque); avoid using armrests to push up out of chairs (use leg musculature).
Contemporary "Keep Your Move in the Tube"
Many modern surgical rehabilitation programs have adopted load-based biomechanical rules: patients keep their upper arms close to their torso (inside an imaginary tube), keeping the humerus adducted during functional tasks. This eliminates high-torque levers and lateral sternal distraction forces, permitting earlier safe functional upper-extremity movement.
ACS Classification & Revascularization Comparison Table
Clinical Entity Pathology & Mechanism ECG Findings Biomarkers (Troponin) Primary Revascularization / Medical Strategy
Stable Angina Fixed epicardial stenosis (>70%); demand ischemia Normal at rest; transient horizontal ST depression on GXT Negative Anti-anginal therapy (Beta-blockers, Nitrates, CCBs); elective PCI if refractory
Unstable Angina (UA) Fissured plaque with transient, subocclusive thrombus ST depression, T-wave inversion, or normal Negative Urgent coronary angiography, DAPT, therapeutic anticoagulation
NSTEMI Non-occlusive thrombus or microemboli; subendocardial necrosis Persistent or dynamic ST depression, deep T-wave inversion Positive (Elevated hs-cTn) Early invasive angiography (<24h), PCI with DES, DAPT for 6–12 months
STEMI Complete, acute transmural occlusive thrombus ST elevation ≥ 1 mm \ge 1\text{ mm} ≥ 1 mm in ≥ 2 \ge 2 ≥ 2 contiguous leads (or new LBBB) Positive (Elevated hs-cTn) Immediate primary PCI (D2B <90 min); fibrinolysis if transport >120 min; DAPT 12+ months
Post-CABG Surgical bypass using LIMA, SVG, or radial artery Non-specific baseline ST-T changes common post-op Transient post-op elevation normal Sternal precautions 6–8 weeks, antiplatelet therapy, secondary prevention statin
Clinical Scenario: Exercise Prescription Post-PCI with Stent Thrombosis Risk
A 54-year-old male with an acute NSTEMI underwent PCI with two drug-eluting stents to the mid-LAD two weeks prior to starting Phase II cardiac rehabilitation. During intake, he mentions he stopped taking ticagrelor three days ago because of mild bruising on his arms:
Clinical Emergency Assessment: Bruising is an expected, non-threatening side effect of platelet inhibition. Abrupt cessation of ticagrelor creates extreme vulnerability to acute stent thrombosis in the freshly stented LAD.
Immediate Action: The rehabilitation clinician must withhold exercise testing and training, immediately contact the patient's cardiologist, and ensure the patient resumes his prescribed P 2 Y 12 P2Y_{12} P 2 Y 12 inhibitor without delay.
Rehabilitation Guidance: Emphasize that DAPT must be continued for at least 6 to 12 months, explaining that while minor bruising is benign, stent thrombosis carries a 20–45% risk of fatal re-infarction.